530145-11-0

Usage

Uses

Used in Pharmaceutical Industry:
(E)-Ethyl 3-(4-(hydroxymethyl)phenyl)prop-2-enoate is used as an intermediate for the synthesis of new pharmaceutical compounds due to its unique chemical structure, contributing to the development of novel drugs with potential therapeutic benefits.
Used in Fragrance Industry:
(E)-Ethyl 3-(4-(hydroxymethyl)phenyl)prop-2-enoate is used as a fragrance ingredient for its sweet, floral scent, enhancing the aroma of various personal care products.
Used in Personal Care Products:
(E)-Ethyl 3-(4-(hydroxymethyl)phenyl)prop-2-enoate is used as an additive in perfumes and cosmetics, providing a pleasant scent and improving the overall sensory experience of these products.

Upstream product

• 51828-89-8 ethyl 4-formylcinnamate 

Relevant academic research and scientific papers

PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE

The present invention provides a compound represented by formula [I] shown below or a pharmaceutically acceptable salt thereof that has an inhibitory effect on 20-HETE producing enzyme. (in formula [I] above, the structure represented by formula [II] below: represents any of the structures represented by formula group [III] below: R1, R2, R3, and R4 independently represent a hydrogen atom, a fluorine atom, methyl, or the like, R5 represents any of the structures represented by formula group [IV]:

NOVEL COMPOUNDS AS DUAL INHIBITORS OF PHOSPHODIESTERASES AND HISTONE DEACETYLASES

It relates to certain compounds having a polycyclic structure and a hydroxamic acid moiety, wherein the polycyclic structure comprises at least three ring systems, wherein one ring system is a polycyclic ring system comprising from 2 to 4 rings; at least one ring is an aromatic ring; and wherein the structure comprises at least 3 nitrogen atoms and 1 oxygen atom. It also relates to a process for their preparation, as well as to pharmaceutical compositions containing them, and to their use in medicine, in particular in the treatment and/or prevention of neurological disorders coursing with a cognition deficit or impairment, or neurodegenerative diseases. wherein B1 is a radical selected from the group consisting of formula (A"), formula (B"), formula (C"), and formula (D"):